…
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Apnimed, Inc. appears to be a clinical-stage biopharmaceutical company focused on developing therapies for sleep-disordered breathing and related cardiorespiratory conditions. Long-term growth may be driven by addressing an unmet need in obstructive sleep apnea, potential clinical-stage product advancement, and broader demand for non-device treatment options that could support adoption.
Key investment risks include the high probability of clinical or regulatory setbacks, the need for additional financing to reach commercialization, limited operating history and commercial track record, and competitive pressure from established device and pharmaceutical players.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| APMD Apnimed, Inc. Common Stock |
- -% |
15.81 | - | - | - | - |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.